NASDAQ:KZR - Kezar Life Sciences Stock Price, Forecast & News

Kezar Life Sciences trades on the NASDAQ under the ticker symbol "KZR."

Kezar Life Sciences Inc (NASDAQ:KZR) posted its quarterly earnings results on Wednesday, November, 6th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.51) by $0.03. View Kezar Life Sciences' Earnings History.

Kezar Life Sciences is scheduled to release their next quarterly earnings announcement on Tuesday, March 24th 2020. View Earnings Estimates for Kezar Life Sciences.

3 Wall Street analysts have issued 12 month target prices for Kezar Life Sciences' shares. Their forecasts range from $15.00 to $15.00. On average, they expect Kezar Life Sciences' stock price to reach $15.00 in the next year. This suggests a possible upside of 358.7% from the stock's current price. View Analyst Price Targets for Kezar Life Sciences.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kezar Life Sciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kezar Life Sciences.

Media stories about KZR stock have been trending very negative this week, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Kezar Life Sciences earned a media sentiment score of -3.6 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Kezar Life Sciences.

Some companies that are related to Kezar Life Sciences include Seres Therapeutics (MCRB), Syndax Pharmaceuticals (SNDX), Theratechnologies (THERF), Affimed (AFMD), Cerecor (CERC), Aeglea Bio Therapeutics (AGLE), Advanz Pharma (CXRXF), Ocular Therapeutix (OCUL), LifeVantage (LFVN), Theratechnologies (THTX), Tyme Technologies (TYME), GlycoMimetics (GLYC), Monopar Therapeutics (MNPR), Chiasma (CHMA) and XOMA (XOMA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Kezar Life Sciences investors own include Zoetis (ZTS), ACADIA Pharmaceuticals (ACAD), Agile Therapeutics (AGRX), Align Technology (ALGN), BIOLINERX LTD/S (BLRX), Audentes Therapeutics (BOLD), Exelixis (EXEL), Amicus Therapeutics (FOLD), Global Blood Therapeutics (GBT) and Gilead Sciences (GILD).

(KZR) raised $70 million in an initial public offering on Thursday, June 21st 2018. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen, Wells Fargo Securities and William Blair acted as the underwriters for the IPO.

Shares of KZR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of KZR stock can currently be purchased for approximately $3.27.

Kezar Life Sciences has a market capitalization of $62.59 million. The company earns $-23,170,000.00 in net income (profit) each year or ($2.26) on an earnings per share basis. Kezar Life Sciences employs 24 workers across the globe.View Additional Information About Kezar Life Sciences.

The official website for Kezar Life Sciences is http://www.kezarlifesciences.com/.

Kezar Life Sciences' mailing address is 4000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-822-5600 or via email at [email protected]